You are viewing: US Oral Proteins & Peptides Market analysis

The US Oral Proteins & Peptides Market was valued at $1957.2 Million in 2025 and projected to reach to $5831 Million by 2030, representing a compound annual growth rate of 24.4%. The US oral proteins and peptides market is positioned for exceptional growth through 2030, driven by technological breakthroughs in formulation science and increasing patient preference for oral administration over injectable therapies.

US Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Oral Proteins & Peptides Market Trends and Insights

  • This represents a compound annual growth rate of 24.4%, significantly outpacing global trends.
  • The US market benefits from advanced healthcare infrastructure, strong pharmaceutical R&D capabilities, and increasing adoption of oral delivery technologies that enhance bioavailability and patient compliance. Driving this growth, the US faces rising demand for non-invasive therapeutic alternatives and improved treatment options for chronic diseases including diabetes, gastrointestinal disorders, and metabolic conditions.
  • The US regulatory environment, led by the FDA, continues to support innovation in oral peptide formulations and delivery mechanisms.
  • Between 2025 and 2030, the US market will be shaped by breakthrough technologies, expanded clinical applications, and growing investment from both established pharmaceutical companies and emerging biotech firms focused on oral peptide therapeutics..

Key Market Statistics

  • CAGR (2025-2030) 24.4% CAGR
  • Market Size, 2025 ~USD 1957.2 Million
  • Forecast, 2030 ~USD 5831 Million
  • Country US

US Oral Proteins & Peptides Market Overview

Market Valuation & Growth :

The US oral proteins and peptides market is valued at $1,957.2 million in 2025, with a robust CAGR of 24.4% through 2030, significantly exceeding the global growth rate of 22.1%.

Advanced Healthcare Infrastructure :

The US benefits from world-class pharmaceutical R&D capabilities, FDA regulatory frameworks, and sophisticated healthcare systems that accelerate innovation and adoption of oral delivery technologies.

Oral Delivery Innovation :

Increasing adoption of advanced oral delivery technologies in the US is driving market expansion, enabling better bioavailability and patient compliance for protein and peptide therapeutics.

Forecast Growth Trajectory :

The market is projected to reach $5,831 million by 2030, representing nearly 3x growth over five years, driven by rising demand for non-invasive therapeutic options and chronic disease management.

US Oral Proteins & Peptides Market Dynamics

  • Strong pharmaceutical investment, favorable regulatory pathways, and expanding applications in diabetes, obesity, and gastrointestinal disorders are key growth catalysts.
  • The US market's outperformance relative to global trends reflects its mature healthcare ecosystem and early adoption of innovative delivery platforms.
  • Competitive intensity is expected to increase as major pharmaceutical companies and biotech firms invest heavily in oral peptide development, creating opportunities for market consolidation and strategic partnerships..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • The US oral proteins and peptides market will nearly triple from $1,957.2M (2025) to $5,831M (2030), driven by 24.4% CAGR.
    • The US leads in oral delivery innovation, supported by FDA regulatory pathways and strong biotech investment ecosystems.
    • The US demand is fueled by patient preference for non-invasive therapies and treatment of chronic metabolic and gastrointestinal diseases.
    • The US competitive landscape includes both multinational pharmaceutical giants and specialized biotech firms developing next-generation oral peptide formulations.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    US Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS3163.43611.64106.44736.35523.264517488.28744.216.3
    HOSPITALS & SPECIALTY CLINICS836.9938.71048.31187.41359.51558.81775.82034.814.2
    LONG-TERM CARE FACILITIES1263.31436.116261867.62168.72522.52915.93390.915.8
    TOTAL5263.65986.46780.67791.39051.510532.312179.814169.915.9

    Target Audience

    • Pharmaceutical Companies : US-based and international pharma firms need detailed market intelligence to guide R&D investments, clinical trial planning, and commercialization strategies for oral protein and peptide products in America.
    • Biotech & Life Sciences Firms : Emerging biotech companies require US market data to assess funding opportunities, competitive positioning, and partnership potential in the rapidly expanding oral delivery therapeutics sector.
    • Healthcare Investors & PE Firms : Investment professionals need comprehensive US market analysis to evaluate portfolio opportunities, identify acquisition targets, and assess growth potential in the oral proteins and peptides space.
    • Medical Device & Delivery Companies : Manufacturers of oral delivery systems and formulation technologies require US-specific market insights to understand demand drivers, regulatory requirements, and commercialization pathways.
    • Healthcare Consultants & Advisors : Strategy consultants and business advisors need detailed US market data to support client engagements, competitive analysis, and strategic planning in the oral therapeutics sector.

    Key Companies in the US Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • US-Specific Market Sizing : Obtain precise valuation data for the US market ($1,957.2M in 2025) with detailed forecasts through 2030, enabling accurate financial planning and investment decisions tailored to the American market.
    • Competitive Landscape Intelligence : Understand the competitive dynamics specific to the US market, including key players, market share distribution, and strategic positioning of pharmaceutical and biotech companies operating in oral proteins and peptides.
    • Regulatory & Reimbursement Insights : Access detailed analysis of FDA approval pathways, insurance coverage trends, and reimbursement strategies specific to US oral protein and peptide therapeutics, critical for market entry and commercialization.
    • Technology & Innovation Trends : Identify emerging oral delivery technologies, formulation innovations, and R&D investments driving growth in the US market, helping stakeholders stay ahead of competitive developments.
    • Strategic Growth Opportunities : Discover high-potential therapeutic areas, unmet medical needs, and market gaps within the US oral proteins and peptides sector to guide product development and market expansion strategies.

    Frequently asked questions

    What is the current size of the US oral proteins and peptides market?

    The US oral proteins and peptides market is valued at $1,957.2 million in 2025 and is expected to grow to $5,831 million by 2030.

    What is the projected growth rate for the US market through 2030?

    The US market is projected to grow at a compound annual growth rate (CAGR) of 24.4% from 2025 to 2030.

    What are the primary drivers of growth in the US oral proteins and peptides market?

    Key drivers include rising demand for non-invasive therapeutic alternatives, increasing prevalence of chronic diseases, FDA support for oral peptide innovations, and advances in delivery technologies that improve bioavailability.

    Which therapeutic areas are driving demand in the US market?

    The US market is primarily driven by applications in diabetes management, gastrointestinal disorders, metabolic diseases, and other chronic conditions where oral peptide therapies offer advantages over injectable alternatives.

    How does the US market compare to global trends?

    The US market grows at 24.4% CAGR, significantly faster than the global market CAGR of 22.1%, reflecting the US's advanced healthcare infrastructure and innovation leadership in oral peptide delivery.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status